

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-18 (Cancelled).

19. (New): An oral dosage form comprising:

(i) an erodable core which comprises 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or hydrate thereof, and metformin or a pharmaceutically acceptable salt thereof,

(ii) an erodable coating around said core, which coating comprises one or more openings leading to the core, wherein the coating is erodable in the pH range from 4.5 to 8,

wherein the oral dosage form comprises 2, 4 or 8 mg of 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and 250, 500, 850 or 1000mg of metformin.

20. (New): An oral dosage form according to claim 19, wherein the coating comprises one or more openings extending substantially completely through the coating but not substantially penetrating the core and communicating from the environment of use to the core and wherein release of 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or hydrate thereof, and metformin or a pharmaceutically acceptable salt thereof, from the core occurs substantially through the one or more openings and through erosion of the coating.

21. (New): The oral dosage form according to claim 19, wherein the coating is an enteric coating.

22. (New): The oral dosage form according to claim 21, wherein the enteric coating is non-permeable.

23. (New): The oral dosage form according to claim 19, wherein the core is formulated to provide immediate release of both 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or hydrate thereof, and metformin or a pharmaceutically acceptable salt thereof.

24. (New): The oral dosage form according to claim 19, wherein the dosage form is a tablet form.

25. (New, Withdrawn): A process for the preparation of the oral dosage form according to claim 19, which process comprises:

- (a) preparing an erodable tablet core comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or hydrate thereof, and metformin or a pharmaceutically acceptable salt thereof;
- (b) coating the core with a material that erodes in the pH range from 4.5 to 8; and
- (c) forming one or more openings in the coating.

26. (New, Withdrawn): A method for the treatment of diabetes mellitus, metabolic syndrome, impaired glucose tolerance or impaired fasting glucose which method comprises administering the oral dosage form according to claim 19 to a human or non-human mammal in need thereof.